Phillips et al. showed the improved benefit of T-DM1 in combination with pertuzumab in xenograft models of breast cancer (24). In their study, dual targeting of HER2 with the combination of T-DM1 and pertuzumab resulted in synergistic inhibition of cell proliferation and induction of apoptotic cell death. The gene discussed is ERBB2; the disease is breast cancer.